Law360, The Deal, Global Legal Chronicle | Menarini to Buy Stemline Therapeutics

Alston & Bird client Nuvectis Pharma Inc., an oncology-focused biopharmaceutical company based in Fort Lee, NJ, has announced the closing of its initial public offering (IPO) of 3.2 million shares of common stock at a price of $5 per share, for gross proceeds of $16 million before deducting underwriting discounts and offering expenses.  All shares of common stock were offered by Nuvectis.

Alston & Bird client Journey Medical Corp., a pharmaceutical company based in Scottsdale, AZ, completed its initial public offering (IPO) of 3,520,000 shares of common stock at a price to the public of $10 per share for gross proceeds of $35.2 million, before deducting underwriting discounts and offering expenses. All the shares of common stock were offered by Journey Medical.

Matt Mamak, Robyn Downing, Laura Giambalvo, Bryan Skelton, and Kirk Ekena are noted for representing OncoSec Medical Incorporated in a $42 million public offering of common stock.

Alston & Bird client TG Therapeutics, a biopharmaceutical company developing novel treatments for certain blood cancers and autoimmune diseases, closed an upsized public offering of common stock that raised $300 million.

Mark McElreath, Gerard Hart, Joel Jung, Natalie Clayton, and Ravi Shah are noted for representing Mustang Bio Inc. in its $40 million public notes offering.